CSL enters into Strategic Option and License Agreement with Translational Sciences
- Category: More News
- Published on Thursday, 27 October 2022 10:33
- Hits: 1665
Option to acquire exclusive, global license to enhanced thrombus dissolving drug candidate TS23
KING OF PRUSSIA, PA, USA I October 26, 2022 I Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23.
TS23 is a first-in-class anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as pulmonary embolism (PE) and acute ischemic stroke (AIS). The drug candidate is soon to be evaluated in the United States in the NAIL-IT Phase 2 study, which has been designed to evaluate the safety and thrombolytic effect of ascending doses of TS23 in patients with intermediate-risk acute PE.
“We continue to evolve as a leading biotechnology company which is driven by its promise to patients with purposeful diversity in therapeutic areas, scientific platforms and strategic alliances, and today’s announcement is a further example of this,” said CSL’s Vice President R&D, Hematology Therapeutic Area, Brahm Goldstein M.D.
“Pulmonary embolism is a condition of large unmet need, and we look forward to monitoring the Phase 2 study of TS23 to see how this promising treatment candidate could potentially help patients,” he said.
Translational Sciences Chief Scientific Officer, Guy Reed said “The safe dissolution of pulmonary emboli may prevent serious, disabling complications and death. We are pleased that CSL recognized the therapeutic potential of TS23, and we look forward to collaborating with them into the future.”
In a Phase 1 study in healthy volunteers TS23 was found to be safe, and demonstrated dose-related inactivation of α2-antiplasmin. Thrombus dissolution was also demonstrated by biomarkers in vivo and by testing ex vivo.
The terms of the agreement were not disclosed.
About Translational Sciences
Translational Sciences is clinical stage, biopharmaceutical company with laboratories based in Phoenix, Arizona. Translational Sciences focuses on developing first-in-class therapeutics for the safe and effective treatment of acute cardiovascular diseases and ischemic stroke.
For more information visit https://translationalsciences.com/
CSL Limited (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL.
For more information visit csl.com.